Core Viewpoint - The announcement by Tongyuan Kang Pharmaceutical regarding the inclusion of three innovative drugs in the upcoming ESMO conference highlights the early clinical value recognized by the international academic community [1] Group 1: Drug Highlights - The CDK2/4 inhibitor TY-00540 shows broad anti-tumor potential, demonstrating strong inhibitory effects on key targets such as CDK2/CycA2 and CDK4/CycD1, with significant efficacy in breast and ovarian cancers [2] - The CDK7 inhibitor TY-2699a exhibits high selectivity for CDK7, with preclinical studies confirming its ability to inhibit cancer cell growth at non-toxic doses to normal cells, showing promising safety and efficacy in early clinical data [3] - The differentiated CDK4/6 inhibitor TY-302 presents a better treatment experience with lower gastrointestinal side effects and manageable hematological toxicity, demonstrating significant efficacy and safety in combination therapy for HR+/HER2- advanced breast cancer [4]
同源康医药(02410)三款创新药研究成果获2025年ESMO大会收录